[HTML][HTML] BNT162b vaccines protect rhesus macaques from SARS-CoV-2
…, A Muik, M Vormehr, LM Kranz, KC Walzer… - Nature, 2021 - nature.com
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are
sufficient to immunize large populations. Here we report the preclinical development of two …
sufficient to immunize large populations. Here we report the preclinical development of two …
A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
…, A Muik, M Vormehr, LM Kranz, KC Walzer… - BioRxiv, 2020 - biorxiv.org
To contain the coronavirus disease 2019 (COVID-19) pandemic, a safe and effective
vaccine against the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is …
vaccine against the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is …
Exposure to BA. 4/5 S protein drives neutralization of Omicron BA. 1, BA. 2, BA. 2.12. 1, and BA. 4/5 in vaccine-experienced humans and mice
…, H Hefesha, H Cai, Q Yang, KC Walzer… - Science …, 2022 - science.org
The SARS-CoV-2 Omicron variant and its sublineages show pronounced viral escape from
neutralizing antibodies elicited by vaccination or prior SARS-CoV-2 variant infection owing to …
neutralizing antibodies elicited by vaccination or prior SARS-CoV-2 variant infection owing to …
[HTML][HTML] A trans-amplifying RNA vaccine strategy for induction of potent protective immunity
T Beissert, M Perkovic, A Vogel, S Erbar, KC Walzer… - Molecular therapy, 2020 - cell.com
Here, we present a potent RNA vaccine approach based on a novel bipartite vector system
using trans-amplifying RNA (taRNA). The vector cassette encoding the vaccine antigen …
using trans-amplifying RNA (taRNA). The vector cassette encoding the vaccine antigen …
[HTML][HTML] Hybrid core-shell particles for mRNA systemic delivery
…, S Briançon, IS Keil, F Vascotto, KC Walzer… - Journal of Controlled …, 2023 - Elsevier
mRNA based infectious disease vaccines have opened the venue for development of novel
nucleic acids-based therapeutics. For all mRNA therapeutics dedicated delivery systems are …
nucleic acids-based therapeutics. For all mRNA therapeutics dedicated delivery systems are …
Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins
T Beissert, L Koste, M Perkovic, KC Walzer… - Human Gene …, 2017 - liebertpub.com
Among nucleic acid–based delivery platforms, self-amplifying RNA (saRNA) vectors are of
increasing interest for applications such as transient expression of recombinant proteins and …
increasing interest for applications such as transient expression of recombinant proteins and …
[HTML][HTML] In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET
…, KC Walzer, I Miederer, N Bausbacher, C Loquai… - EJNMMI research, 2018 - Springer
Background [ 18 F]Fluoro-2-deoxy-2-d-glucose positron emission tomography (FDG-PET) is
commonly used in the clinic for diagnosis of cancer and for follow-up of therapy outcome. …
commonly used in the clinic for diagnosis of cancer and for follow-up of therapy outcome. …
BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2
…, A Muik, M Vormehr, LM Kranz, KC Walzer… - bioRxiv, 2020 - biorxiv.org
A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to
immunise large populations. We report the preclinical development of two BNT162b vaccine …
immunise large populations. We report the preclinical development of two BNT162b vaccine …
Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response
F Vascotto, J Petschenka, KC Walzer, M Vormehr… - …, 2019 - Taylor & Francis
TLR7 agonists are considered promising drugs for cancer therapy. The currently available
compounds are not well tolerated when administered intravenously and therefore are …
compounds are not well tolerated when administered intravenously and therefore are …
Dexamethasone premedication suppresses vaccine-induced immune responses against cancer
…, Y Oei, V Javinal, L Delamarre, KC Walzer… - …, 2020 - Taylor & Francis
Glucocorticosteroids (GCS) have an established role in oncology and are administered to
cancer patients in routine clinical care and in drug development trials as co-medication. Given …
cancer patients in routine clinical care and in drug development trials as co-medication. Given …